Cargando…

A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2

BACKGROUND: Many histone deacetylase (HDAC) inhibitors are well recognized as potential anti-cancer drugs. Inhibition of HDACs induces temporal transcription or epigenetic control, thus regulating many different biological responses. Here, we investigated the osteogenic effect of the HDAC inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Zang Hee, Kim, Hyun-Jung, Ryoo, Hyun Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Bone and Mineral Research 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466445/ https://www.ncbi.nlm.nih.gov/pubmed/26082914 http://dx.doi.org/10.11005/jbm.2015.22.2.51

Ejemplares similares

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth
por: Said, Thenaa K, et al.
Publicado: (2001)

Suberoylanilide hydroxamic acid represses glioma stem-like cells
por: Hsu, Che-Chia, et al.
Publicado: (2016)

ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
por: Wu, Ji‐cheng, et al.
Publicado: (2018)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Suberoylanilide hydroxamic acid during in vitro culture improves development of dog-pig interspecies cloned embryos but not dog cloned embryos
por: KIM, Min Jung, et al.
Publicado: (2018)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases
por: Verrillo, Lucia, et al.
Publicado: (2023)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

Suberoylanilide Hydroxamic Acid Attenuates Autoimmune Arthritis by Suppressing Th17 Cells through NR1D1 Inhibition
por: Kim, Da Som, et al.
Publicado: (2019)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid
por: Rodgers, Cooper D, et al.
Publicado: (2019)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Chlorinated Polyketide Obtained from a Daldinia sp. Treated with the Epigenetic Modifier Suberoylanilide Hydroxamic Acid
por: Du, Lin, et al.
Publicado: (2014)

Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin‐related protein 14‐mediated autophagy
por: Zhen, Zijun, et al.
Publicado: (2017)

Effects of Suberoylanilide Hydroxamic Acid (SAHA) on the Inflammatory Response in Lipopolysaccharide-Induced N9 Microglial Cells
por: Çelik, Zülfinaz Betül, et al.
Publicado: (2022)

Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells
por: Li, Jia-Yao, et al.
Publicado: (2023)

Cardiomyogenic Differentiation of Human Dental Follicle-derived Stem Cells by Suberoylanilide Hydroxamic Acid and Their In Vivo Homing Property
por: Sung, Iel-Yong, et al.
Publicado: (2016)

Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells
por: Sun, Pei-Chang, et al.
Publicado: (2010)

Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines
por: Oertel, Susanne, et al.
Publicado: (2011)

The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells
por: Chen, Shuo, et al.
Publicado: (2013)

Epigenetic therapy potential of suberoylanilide hydroxamic acid on invasive human non-small cell lung cancer cells
por: Zhang, Shirong, et al.
Publicado: (2016)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
por: Huang, Huichao, et al.
Publicado: (2022)

Suberoylanilide hydroxamic acid suppresses hepatic stellate cells activation by HMGB1 dependent reduction of NF-κB1
por: Wang, Wenwen, et al.
Publicado: (2015)

Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Enhances Radiosensitivity and Suppresses Lung Metastasis in Breast Cancer In Vitro and In Vivo
por: Chiu, Hui-Wen, et al.
Publicado: (2013)

Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein–Barr virus-associated T cell and natural killer cell lymphoma
por: Siddiquey, Mohammed NA, et al.
Publicado: (2014)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
por: Bocchi, Leonardo, et al.
Publicado: (2019)

Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines
por: Feng, Xiuyan, et al.
Publicado: (2016)

Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells
por: Zhou, Weiqiang, et al.
Publicado: (2016)

Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid Exerts Anti-Neoplastic Effects in Acute Myeloid Leukemia Cells
por: Abou Najem, Sonia, et al.
Publicado: (2019)

Suberoylanilide Hydroxamic Acid Induces Hypersensitivity to Radiation Therapy in Acute Myelogenous Leukemia Cells Expressing Constitutively Active FLT3 Mutants
por: Chen, Xufeng, et al.
Publicado: (2013)

Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells
por: You, Bo Ra, et al.
Publicado: (2017)

HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury
por: Ruess, Dietrich A., et al.
Publicado: (2016)

Transcriptional profiling of suberoylanilide hydroxamic acid (SAHA) regulated genes in mineralizing dental pulp cells at early and late time points
por: Duncan, Henry F., et al.
Publicado: (2015)

In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model
por: Thiemann, Markus, et al.
Publicado: (2012)

Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms
por: Liu, Zhaohui, et al.
Publicado: (2014)

Discovery of Primarolides A and B from Marine Fungus Asteromyces cruciatus Using Osmotic Stress and Treatment with Suberoylanilide Hydroxamic Acid
por: Igboeli, Hope A., et al.
Publicado: (2019)

Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance
por: Fujimoto, Tomokazu, et al.
Publicado: (2021)

Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells
por: Han, Han, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jvvu8s89498sgafb99hibfuj1l